NANOBIOTIX (NASDAQ: NBTX) announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV for the investigational, potential first-in-class radioenhancer NBTXR3. Nanobiotix will grant Janssen a worldwide license for the development and commercialization of NBTXR3 and Nanobiotix will receive near term cash and operational support valued up to $60 million and is eligible for success-based payments of up to $1.8 billion.
Tivic Health Systems, Inc. (NASDAQ: TIVC) announced that it intends to offer and sell shares of its common stock in a public offering.
Biodexa (NASDAQ: BDRX) announced completion of enrollment and treatment of nine paediatric patients into the ongoing Phase 1 study of MTX-110 in newly diagnosed Diffuse Midline Gliomas (DMGs).
Black Diamond Therapeutics (NASDAQ: BDTX) shares are up during premarket hours after RA Capital Management acquired 935,850 shares of the company at $5 per share, totaling approximately $4.68 million.
Biophytis SA (NASDAQ CM: BPTS) announced that it has filed for approval on the FDA portal to launch its SARA-31 program in the US, the first ever Phase 3 study in sarcopenia. Biophytis expects a response from the regulatory authorities during the third quarter of 2023.
Nymox Pharmaceutical Corporation (OTC: NYMXF) announced that two former employees of the company proposed a potential transaction. The terms of the Proposed Transaction were thoroughly reviewed and it was determined that it was not in the best interests of Nymox or its shareholders.
Marker Therapeutics, Inc. (NASDAQ: MRKR) announced that zedenoleucel (MT-401) was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) announced the publication of data demonstrating the role of inflammasome NLRP3 activation in hypertrophic heart disease induced by mechanical stress in vivo studies in various animal models.
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) announced that it has entered into a worldwide, exclusive license agreement with CAMP4 Therapeutics Corp, where Fulcrum will advance the discovery, development, and commercialization of novel therapeutic agents against an undisclosed target for the potential treatment of Diamond-Blackfan Anemia (DBA).
